145th Meeting of the National Advisory Council on Drug Abuse
Hybrid Meeting – September 12, 2023
Closed Session
This meeting is closed to the public in accordance with the provisions set forth in section 552b{c}(4) and 552b{c}(6), Title 5, U.S. Code and section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).
Time | Presentation |
---|---|
10:30 a.m. | Call to Order Nora Volkow, M.D. Director, NIDA Review of Policy and Procedures Susan Weiss, Ph.D. Executive Secretary National Advisory Council on Drug Abuse Director, Division of Extramural Research, NIDA |
10:45 a.m. |
Council Review of Grant Applications Division of Therapeutics and Medical Consequences (DTMC) Division of Neuroscience and Behavior (DNB) Office of Research Training, Diversity, and Disparities (ORTDD) Division of Epidemiology, Services, and Prevention Research (DESPR) Office of Translational Initiatives and Program Innovationa (OTIPI) |
11:45 p.m. | Break |
Videocast:
Members of the public who may wish to express views regarding any items discussed during this meeting may do so by writing Gillian Acca, within ten days of the meeting. Any written statements by members of the public will receive careful consideration.
Join the Videocast
Open Session
Hybrid meeting: 6001 Executive Blvd, North Bethesda, MD.
Time | Presentation |
---|---|
1:00 p.m. | Welcome and Opening Remarks Nora Volkow, M.D., Director, NIDA |
1:15 p.m. | Director's Report Nora Volkow, M.D., Director, NIDA |
2:05 p.m. | Discussion Council Members |
2:30 p.m. | Substance Use in the Context of HIV and National HIV Efforts Harold Phillips, MRP, Director White House Office of National AIDS Policy |
3:15 p.m. | Updates from NIDA’s HIV Research Program Redonna K. Chandler, Ph.D. Director, HIV Research Program |
3:45 p.m. | Xylazine and Opioids – Clinical Experiences and Research Questions Kristen Huntley, Ph.D. Associate Director Center for the Clinical Trials Network |
4:15 p.m. | Concept Clearances
|
4:45 p.m. | Public Comments |
5:00 p.m. | Adjourn |